If high brain Aβ levels are one of the required factors to trigger AD, yet not the only cause, detecting abnormal Aβ and perhaps tau conformational changes, spreading, deposition and mislocalization at early AD stages may lead to define a time frame in which initial beneficial microglial inflammatory responses are ongoing and immunomodulation strategies thus may prove more effective. This evidence concerns the gene MAPT and Alzheimer disease.